LFG
PRME icon

Larson Financial Group’s Prime Medicine PRME Stock Holding History

Larson Financial Group’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-6
Closed -$33 – 3621
2025
Q3 		$33 Sell
6
-194
-97% -$788 ﹤0.01% 3375
2025
Q2 		$494 Hold
200
– – ﹤0.01% 2862
2025
Q1 		$398 Buy
+200
New +$510 ﹤0.01% 2634

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Larson Financial Group's PRME Position: Q4 2025 in Review

Larson Financial Group sold out of Prime Medicine (PRME) in Q4 2025, closing a stake of 6 shares — an estimated $33 sold.

Larson Financial Group first reported a position in PRME in Q1 2025 and held it in 3 quarters. The position peaked at $494 in Q2 2025. 183 funds tracked by Wall St. Rank hold PRME as of Q4 2025.

  • Larson Financial Group reported no remaining Prime Medicine position as of Q4 2025 after selling out during the quarter.
  • Larson Financial Group sold 6 Prime Medicine shares in Q4 2025, an estimated $33.
  • Larson Financial Group first reported a position in Prime Medicine in Q1 2025 and held it in 3 quarters.
  • Larson Financial Group's Prime Medicine position peaked at $494 in Q2 2025.
  • 183 funds tracked by Wall St. Rank held Prime Medicine as of Q4 2025.

Based on Larson Financial Group's 13F filing for Q4 2025, filed 6 Feb 2026.